much reaction thus far in the united states but of course we will bring that as and when we get it. let s pause for a moment and get a check on the sport. after 2a seasons and six super bowl titles, bill belichick is leaving the new england patriots. it ends an era of historic success at the nfl franchise, with its owner calling belichick the best coach of all time. despite his achievements in new england, the patriots lost 13 of their 17 regular season games in 2023, finishing bottom of their division and handing belichick his worst ever win?loss record for a season. all nine super bowl appearances came alongside tom brady, but once the quarterback left, the patriots only reached the playoffs one more time. belichick is 71, but he s only 1a wins behind the legendary dawn shula wins behind the legendary don shula in all time nfl victories and is likely to continue his career elsewhere. after a series of discussions with meet robert and i have agreed i have agreed mutually to
grows, it is a disease where you d have disordered genomes. so your genetic makeup changes as the cancer evolves, and as a result of that, understanding the changes in the dna of your tumour understanding the changes in the dna of yourtumourare understanding the changes in the dna of your tumour are very very important. that can help us choose the therapy, the right therapy for the therapy, the right therapy for the right patient, it can also help us understand the potential outcomes for the patients and today what we ve identified is essentially the basis for expanding the use of sequencing as much as you and i can today, over our genetic code, and what that means is that there will be more genome sequencing in the national health service and what that will achieve is better cancer care. ., y ., that will achieve is better cancer care. . i” that will achieve is better cancer care. ., ., care. can you look explain that oint to care. can you look explain that point to me? care. can
patient? and the care that you give to that atient? ~ ., and the care that you give to that atient? ~ . ., , ., patient? well, what we were able to do in this study patient? well, what we were able to do in this study is patient? well, what we were able to do in this study is to patient? well, what we were able to do in this study is to combine - do in this study is to combine clinical data by following the patients over a long period of time, and that allowed us to see changes in their dna to make a difference in outcomes. in some of those cases, that identified particular treatments that those patients would benefit from, and we can choose those treatments in some settings based on the genetic makeup. otherwise, what we have tended to do in the past is give treatments for specific tumours that now we can do that guided by the low molecular signatures within the tumour and that, it will improve our conservations. , ., , , ., conservations. obviously, genome sequencing conserva